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OBJECTIVES: The purpose of this project was to prepare
and test culturally and linguistically appropriate versions
of the SF-36v.2 in Crow and Salish. Prior translation
efforts (e.g., IQOLA) have shown that cultural as well 
as linguistic considerations must be made when creating
culturally-appropriate versions of the MOS SF-36 
Health Status Survey (SF-36). The populations selected
for this project were two Native American populations 
in Montana who are interested in preserving their native
languages.
METHODS: Representatives of the Confederated Salish
Kootenai Tribes (CSKT) expressed a preference for an
English version of the SF-36; this was based on the need
to preserve a pure form of the native language. Repre-
sentatives of the Crow Tribe eventually decided to not
participate in the study. In spring 2001, four hundred
adult members of the CSKT were randomly selected to
receive a mailed copy of the SF-36v.2 (English) along with
a questionnaire (e.g., demographic, co-morbidity, and
health care encounters), a cover letter, and a ﬁve-dollar
incentive.
RESULTS: Response rate was 51% (205/400). Item-to-
scale correlations ranged from -0.0166 (Pain) to +0.932
(Role-Emotional) with most in the 0.7 to 0.8 range. Scale-
to-General Health Scale correlations were all positive,
ranging from 0.2611 (Pain) to 0.5986 (Mental Health).
The Pain Scale (Items 7 and 8) had the poorest item-to-
scale and scale-to-General Health Scale correlations. The
transformed norm-based z-scores for the CSKT popula-
tion ranged from 38.1688 (Pain) to 48.1198 (Vitality).
CONCLUSIONS: While Native Americans may be inter-
ested in preserving and promoting the use of their native
languages, they may not be interested in doing so in
health surveys. The performance of all scales but the Pain
Scale in the CSKT population appears to be good;
however, further investigation into the Pain Scale results
is needed. It is also important to recognize that other
tribes may have different norms and response issues.
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The role of quality measurement of medication use is
becoming more critical as consumers, employers and
others demand increased accountability and transparency
from the delivery of health care. At this time, however,
there are no explicit quality indicators of preventable
drug-related morbidity (PDRM) that could be used by
clinicians and/or a health care organization.
OBJECTIVES: To create consensus-approved clinical
indicators of PDRM in older adults applicable to the
Canadian health care system.
METHODS: A written survey was constructed, listing the
clinical outcome and pattern of care related to a number
of possible PDRMs in older adults. Using the Delphi 
technique, two independent six-member expert panels
(geriatricians, clinical pharmacologists) in Nova Scotia,
Canada were asked to judge whether the outcome in each
situation was foreseeable and recognizable, and whether
causality was identiﬁable and controllable. The panel
could also suggest additional PDRMs. Subsequently, a
focus group of 12 general practitioners (GPs) evaluated
these PDRM indicators. The inclusion of this third panel
provided a triangulation of expert opinion across three
practice areas.
RESULTS: The two expert panels proposed 58 indicators
of PDRMs in older adults after two rounds of the Delphi
technique. The GPs agreed with 52 (90%) of these PDRM
indicators.
CONCLUSIONS: This study showed that consensus on
quality indicators of PDRM can be reached among
experts. These indicators could be used by a health care
organization to proactively identify patients at risk for a
PDRM and to improve the quality, safety and appropri-
ateness of medication use. Additionally, the indicators
form an important bridge between processes and out-
comes of care and could be used in conjunction with
existing medication use quality indicators. Subsequent
phases of this study will involve pharmacist validation of
these PDRMs, and identiﬁcation (through an integrated
medical database of older Nova Scotians) of patients who
experienced PDRMs.
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Medical journal advertisements have been evaluated for
pharmacoeconomic and quality of life (QoL) content,
however no studies have compared advertisements from
general health care (General) and managed care (MC)
journals.
OBJECTIVES: The speciﬁc objectives of this study were
to: 1) determine the number of pharmacoeconomic and
QoL messages encountered in General and MC journals;
and 2) evaluate the frequency of advertisements with
respect to the type and content of pharmacoeconomic or
QoL messages.
METHODS: The study was a review of all advertisements
in six journals appearing from July 1999–June 2001.
Journals were divided into two categories: General and
MC. Three independent reviewers evaluated the content
of each advertisement, and designated advertisements as
those containing QoL, implicit or explicit, and/or phar-
macoeconomic messages. Advertisements were also 
evaluated based on their use of supporting evidence 
for these messages. Advertisements in General and MC
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journals were compared using descriptive and compara-
tive chi-squared statistics.
RESULTS: 4,036 advertisements were identiﬁed from all
issues in three General and three MC journals with 194
unique advertisements evaluated for potential outcomes
messages. General and MC journals had QoL messages
included in 36.0% and 41.7% of advertisements (p <
0.005) and pharmacoeconomic messages in 7.3% and
9.0% of advertisements (p = 0.08), respectively. MC jour-
nals had more advertisements detailing pharmaceutical
expenditure savings (p = 0.01) and listing speciﬁc costs 
(p = 0.001). Trends for increased implicit QoL (p = 0.07)
and QoL references (p = 0.08) in advertisements were
found in MC journals.
CONCLUSIONS: Leading journals contain large
numbers of QoL advertisements, with MC having signif-
icantly more than General journals. MC journals are 
also more speciﬁc as to the details of the cost data,
however very few advertisements contain these messages.
Increased detail in both QoL and pharmacoeconomic
advertisements will help improve communication of this
timely data.
CARDIOVASCULAR DISEASES/DISORDERS—
Clinical Outcomes Presentations
PCV1
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OBJECTIVE: To perform a systematic review of the 
literature pertaining to the efﬁcacy of amlodipine
monotherapy in reducing systolic blood pressure (SBP) in
a variety of patient subgroups. The sixth report of the
Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure (JNC
VI) recommends diuretics or long-acting dihydropyridine
calcium channel blockers (CCBs) for the treatment of 
isolated systolic hypertension (ISH). Amlodipine is the
most commonly prescribed CCB worldwide; therefore, a
systematic review was performed to capture the impact
of amlodipine monotherapy on SBP. 
METHODS: Following a protocol that had been devel-
oped a priori, published literature in ﬁve languages was
searched from 1980 to 2001, using three electronic data-
bases and manual bibliography checks of recent review
articles and all accepted studies. Randomized controlled
trials with at least 10 patients, one treatment arm of
amlodipine monotherapy, minimum treatment duration
of 8 weeks, reporting baseline and endpoint BP, and pres-
ence of baseline hypertension (deﬁned as SBP ≥140mm
Hg, diastolic blood pressure (DBP) ≥90mmHg, or both)
were accepted for this systematic review.
RESULTS: A total of 696 citations were reviewed, of
which 85 met all inclusion criteria. Comparable treatment
arms were pooled, and weighted means of efﬁcacy results
were calculated. In the amlodipine monotherapy arms,
representing over 5,000 patients treated with the drug,
amlodipine reduced SBP by an average of 17.5mmHg
from baseline (an estimated 13.3mmHg more than
placebo). The effect of amlodipine in reducing SBP was
even more marked in elderly patients (24.1mmHg mean
reduction), black patients (23.9mmHg mean reduction),
and patients with ISH (25.9mmHg mean reduction),
although the number of studies investigating these special
populations was small. 
CONCLUSION: Amlodipine is effective for reducing
SBP. Long-term trials are needed to correlate SBP reduc-
tion with clinical outcomes.
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OBJECTIVES: To quantify the incidence of major
adverse events (AE) occurring in hospital or within 30
days after surgery in patients undergoing coronary artery
bypass grafting (CABG), and identify risk factors for
these AEs. 
METHODS: A systematic review and analysis of studies
published in English since 1990. Studies of isolated 
standard CABG reporting post-operative incidence of
myocardial infarction (MI), stroke, GI bleeding, renal
failure, or death in hospital or within 30 days, were 
eligible. The incidence of these events was calculated
overall, and for selected patient groups deﬁned by: all
elective CABG vs. mixed (elective and urgent/emergency
CABG); mean ejection fraction (EF) <50% vs. >50%;
mean age <60 years vs. >60 years; primary CABG only
vs. some patients with reoperations; RCTs vs. cohort
studies; single center vs. multicenter studies. Odds ratios
of selected AEs were computed according to group risk
factors.
RESULTS: 176 studies (205,717 patients) met all inclu-
sion criteria. The average incidence of major AEs occur-
ring in-hospital was: death -1.7% (range 0%–6.6%),
non-fatal MI—2.4% (range 0%–13.9%), non-fatal
stroke—1.3% (range 0%–3.2%), GI bleeding—1.5%
(range 0.7%–2.7%), and renal failure requiring dialysis—
0.8% (range 0%–6.2%). Thirty-day mortality was 2.1%
(range 0%–7.7%). Subset analyses revealed interesting
differences in overall mortality and MI incidence by
groups with all elective vs. mixed CABG, by study design,
mean age, primary CABG vs. some patients with re-
operation, and by number of study sites. Meta-analyses
of odds ratios suggest that old age (>70 years); female
gender; low EF; history of stroke, MI, or heart surgery;
